For patients who do choose antithrombotic therapy, we suggest aspi- rin (75 mg to 325 mg once daily) rather than www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e533S For patients with AF at low to intermediate risk of stroke (eg, CHADS2 score of 0 or 1) during the rst 12 months after placement of an intracoronary stent (bare metal or drug eluting), we suggest dual antiplatelet ther- apy rather than triple therapy (Grade 2C). At 12 months after intracoronary stent place- ment, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see section 3.1). Remarks: Patients who place an exceptionally high value on stroke reduction and a low value on avoid- ing bleeding and the burden associated with antico- agulant therapy are likely to choose triple therapy rather than dual antiplatelet therapy. Other factors that may in uence this choice are a consideration of bleeding risk and the presence of additional non- CHADS2 risk factors for stroke (see section 2.1.12). 3.3. For patients with AF at intermediate to high risk of stroke (eg, CHADS2 score of 1 or greater) who experience an acute coronary syndrome and do not undergo intracoronary stent place- ment, we suggest for the rst 12 months, adjusted-dose VKA therapy (INR 2.0-3.0) plus single antiplatelet therapy rather than dual antiplatelet therapy (eg, aspirin and clopidogrel) or triple therapy (eg, warfarin, aspirin, and clopidogrel) (Grade 2C). After the rst 12 months, antithrombotic therapy is suggested as for patients with AF and stable coronary artery disease (see section 3.1). 